DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Luma Group
Luma Group
Institutional venture firmNew York, NYlumagroup.comSEC venture capital fund adviseremerging managerone firm, 2 filing advisers
This firm files as 2 advisers on lumagroup.com: Luma Bio-It Management, LLC. Each keeps its own CRD, funds and filings; the grouping is the website each swore to on Form ADV and is recomputed every pass.
Fueling the future of human health and longevity with cutting edge innovations.
venture manager, reported GAV $73M across 1 vehicles
Importance
15
moderate
Active deployment
29
moderate
Emerging
63
high
Completeness
75
high
Freshness
100
high
Research priority
25
moderate
Identity and regulatory footprint
- Headquarters
- New York, NYadviserinfo.sec.gov
- Office address
- 595 MADISON AVENUE, 31ST FLOOR, New York, NY, 10022adviserinfo.sec.gov
- Business phone
- 917-952-7860adviserinfo.sec.gov
- Website
- http://www.lumagroup.com
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 31, 2026
- Private funds reported
- 1 (1 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $70.6Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- business email
- contactus@lumagroup.comlumagroup.compublished by the subject
- business phone
- 917-952-7860adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
1 observed deals
Stated (the firm’s website)
- Sectors
- ai, healthcare, biotech, medtech, energy
- Stages
- multi stage
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation
series a 100%
Stage at first entry
series a 100%
Sectors
unknown 100%
lead rate 0%follow-on rate 0%new logos, 12 months 1
Funds and vehicles
1 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Lumabio I LP | Fund | 2023 form d first sale | Fundraising | $73.0M Nov 20, 2024 | 15 | $107M | Oct 6, 2025 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
13 current, 1 departed
Rishabh Mishra
Board or advisoryClinical Advisor
Themasap Khan
General partnerCo-Founder & Partner
Josh Fink
Managing partnerFounder & Managing Member
Joshua Aaron Fink
Managing partnerManaging Member · since Feb 1, 2023
Richie Santry
OtherChief of Staff
Jamie Kasuboski
PartnerPartner & Head of Research
Themasap Ahmad Khan
PartnerMember · since Nov 1, 2024
Bill Ryan
Platform and operationsChief Financial Officer
Tamara Young
Platform and operationsExecutive Assistant
William Peter Ryan
Platform and operationsChief Financial Officer · since Jul 1, 2024
Negin Mokhtari
Venture partnerVenture Partner & Chief Strategy Officer of LABI
Rosana Kapeller
Venture partnerVenture Partner
John Gomez
Vice presidentSenior Associate
1 departed (kept with end dates)
- Ha Nguyen · Director Of Finance · Feb 1, 2023 to Aug 5, 2024 Inference
Investments on record
1 edges, 1 companies, 0 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| Coultreon Biopharma | Series A · Series A | participant | unknown | $125M | unknown | Apr 28, 2026 | Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
7 relationships from shared deals, counted for the whole firm
Sofinnova Investments, Inc. 1 shared · one time · they led 1Samsara Biocapital, LLC 1 shared · one timeGalapagos 1 shared · one timeBalyasny Asset Management L.P. 1 shared · one timeRegeneron Ventures 1 shared · one timeLongwood Fund 1 shared · one timeFinchley Healthcare Ventures 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
4 dated events
- Aug 5, 2024HA Nguyen (Director Of Finance) no longer on Schedule A of Luma Group
- Jul 1, 2024William Peter Ryan joined Schedule A of Luma Group as Chief Financial Officer
- Sep 25, 2023Luma Group first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Sep 25, 2023Lumabio I LP first reported on Form ADV by Luma Group (Venture Capital Fund), GAV $34,547,986Fund first reported on Form ADVFundsFactLumabio I LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $73M across 1 vehicles
Evidence
44 observations from 3 sources